Phibro Beats Fiscal 2026 Estimates, Then Confirms a Plant Closure

A 17% jump in full-year sales does not usually arrive bundled with a plant-closure notice. Phibro Animal Health delivered both on Wednesday, beating fiscal 2026 estimates across every headline metric while confirming it will shut a manufacturing plant in Chicago Heights, Illinois, by next summer.

Phibro closes fiscal 2026 with a broad beat

Phibro Animal Health closed its fiscal year on June 30 with fourth-quarter net sales of $396.7 million, up 5% year over year and about 7% ahead of Wall Street's $371.6 million estimate. Adjusted diluted earnings per share came in at $0.85, a 17% beat versus the $0.73 consensus; on a GAAP basis, diluted EPS was $0.53, up 26%. Shares jumped roughly 7% to $38.78 on the print.

For the full fiscal year, net sales reached $1.52 billion, up 17% from $1.30 billion. Adjusted EBITDA grew 39% to $255 million, and adjusted diluted EPS climbed 48% to $3.22. Gross margin expanded to 33.8%, from 30.9% a year earlier. The Animal Health segment, which houses the acquired feed-additive line alongside legacy vaccines and pharmaceuticals, generated $1.16 billion of that total, up 21%.

Phibro also confirmed it will close its Chicago Heights, Illinois manufacturing plant by summer 2027, shifting production to other company sites and third-party contract manufacturers and affecting about 100 jobs. Chief executive Dani Bendheim called the move a strategic network decision, tied to consolidating capacity after the company's medicated feed additive business, acquired in October 2024, matured into a full production line.

For fiscal 2027, the company guided to net sales of $1.55 billion to $1.60 billion and adjusted EBITDA of $258 million to $268 million, both implying growth continuing, if at a slower pace.

Why diversification beats pure-play animal health

The consolidation is happening because the acquisition behind it is working. Phibro bought the line from Zoetis in October 2024 for $350 million, and by this spring it was already driving double-digit growth in the Animal Health segment. The fiscal 2026 numbers show that holding through year-end.

That matters next to what's happening one tier up in the category. Zoetis, animal health's largest pure-play, posted flat second-quarter revenue this year as companion-animal spending softened, then folded its chief operating officer role into its finance chief's a week later. Phibro's growth isn't coming from the same shelf. Its Animal Health segment, which now includes the acquired feed-additive line alongside legacy vaccines and pharmaceuticals, grew 21% for the year, a rate no pure companion-animal player has posted this cycle.

That's the case for diversifying into livestock and production-animal nutrition as a hedge against consumer pet-spending cycles, made in actual numbers instead of an investor-day slide. It's also the reason Chicago Heights is closing. Once an acquired business clears its integration runway, the standard next move is network consolidation: fewer plants, more volume per site, better absorption of fixed costs. Bendheim framed the closure as unrelated to the plant's performance, and there's no reason to doubt it. It reads instead as what a company does once an acquisition has already paid for itself and management wants the balance sheet to match the business it has become, not the business it assembled.

For an operator watching from the pet side of the industry, the lesson isn't about Phibro specifically. It's that a category built around pet-owning households is porous enough that a company selling mostly into commercial agriculture just posted the sector's best growth number this earnings season. Diversifying away from consumer pet spending, not deeper into it, is what's working for capital allocators right now.

What the Chicago Heights closure signals for 2027

Three things will determine whether fiscal 2027 holds to that guidance. The first is Brazil: management said its outlook assumes minimal sales there of virginiamycin, a livestock growth-promoting antibiotic still under regulatory review, meaning approval would be straightforward upside rather than a number the company is already counting on. That's a rare case of guidance built conservatively around a live regulatory catalyst.

The second is the Chicago Heights wind-down itself. A plant closing by summer 2027 has to be executed without disrupting the feed-additive supply now driving segment growth. A stumble in shifting output to other Phibro sites or outside contract manufacturers would show up in gross margin before it shows up in a press release.

The third is whether the growth rate holds once the October 2024 acquisition fully laps in year-over-year comparisons. The guided range for fiscal 2027 implies growth slowing to roughly 4% at the midpoint, down from 17% this year. Whether that's conservative guidance or a real deceleration should be clear by the first fiscal-quarter print this fall; Phibro's fiscal first-quarter results have landed in early November each of the past two years.

Source: Phibro Animal Health via Business Wire